Adverse pregnancy outcomes and future risk of heart failure

被引:5
|
作者
Pabon, Maria A. [1 ]
Misra, Amrit [1 ,2 ]
Honigberg, Michael C. [3 ,4 ]
机构
[1] Brigham & Womens Hosp, Div Cardiovasc Med, Boston, MA USA
[2] Boston Childrens Hosp, Dept Cardiol, Boston, MA USA
[3] Massachusetts Gen Hosp, Dept Med, Cardiol Div, Boston, MA USA
[4] Massachusetts Gen Hosp, 185 Cambridge St CPZN 3-187, Boston, MA 02114 USA
关键词
adverse pregnancy outcomes; heart failure; preeclampsia; pregnancy; women's health; GESTATIONAL DIABETES-MELLITUS; CARDIOVASCULAR-DISEASE RISK; ATRIAL-NATRIURETIC-PEPTIDE; LEFT-VENTRICULAR STRUCTURE; HYPERTENSIVE DISORDERS; PLACENTAL ABRUPTION; PRETERM DELIVERY; UNITED-STATES; WOMEN; PREECLAMPSIA;
D O I
10.1097/HCO.0000000000001035
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Purpose of reviewCardiovascular disease (CVD) is the leading cause of death in women. Women with history of adverse pregnancy outcomes (APOs) have approximately two-fold risk of future CVD, but until recently the association with future heart failure (HF) was unclear. Here, we summarize evidence for associations of APOs with HF, potential underlying mechanisms, and future directions for clinical translation.Recent findingsWomen with history of hypertensive disorders of pregnancy (HDPs) have roughly two-fold risk of future HF compared with other parous women even after accounting for interval development of coronary artery disease. The HDPs portend heightened risk of HF with both reduced and preserved ejection fraction. Gestational diabetes mellitus (GDM) and other APOs such as preterm delivery, small-for-gestational-age delivery, and placental abruption may also confer additional risk for HF development. Possible underlying mechanisms linking APOs to HF include shared upstream risk factors and genetics, accelerated development of cardiometabolic risk factors postpartum, persistent endothelial and microvascular dysfunction, and impaired natriuretic peptide signaling.History of APOs, including HDPs and GDM, confer increased risk for development of HF years after delivery. Further research is needed to define strategies to optimize prepregnancy and postpartum cardiovascular health toward HF prevention.
引用
收藏
页码:215 / 222
页数:8
相关论文
共 50 条
  • [41] Proteomic Associations of Adverse Outcomes in Human Heart Failure
    Dib, Marie-Joe
    Levin, Michael G.
    Zhao, Lei
    Diab, Ahmed
    Wang, Zhaoqing
    Ebert, Christina
    Salman, Oday
    Azzo, Joe David
    Gan, Sushrima
    Zamani, Payman
    Cohen, Jordana B.
    Gill, Dipender
    Burgess, Stephen
    Zagkos, Loukas
    van Empel, Vanessa
    Richards, A. Mark
    Doughty, Rob
    Rietzschel, Ernst R.
    Kammerhoff, Karl
    Kvikstad, Erika
    Maranville, Joseph
    Schafer, Peter
    Seiffert, Dietmar A.
    Ramirez-Valle, Francisco
    Gordon, David A.
    Chang, Ching-Pin
    Javaheri, Ali
    Mann, Douglas L.
    Cappola, Thomas P.
    Chirinos, Julio A.
    [J]. JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2024, 13 (05):
  • [42] Association between prediabetes and adverse outcomes in heart failure
    Mai, Linlin
    Wen, Weixing
    Qiu, Min
    Liu, Xiong
    Sun, Lichang
    Zheng, Haoxiao
    Cai, Xiaoyan
    Huang, Yuli
    [J]. DIABETES OBESITY & METABOLISM, 2021, 23 (11): : 2476 - 2483
  • [43] HOME TELEHEALTH REDUCES ADVERSE OUTCOMES IN HEART FAILURE
    Srivastava, Anshul
    Do, Jacquelyn-My
    Ly, Samantha
    Joseph, Jacob
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2017, 69 (11) : 738 - 738
  • [44] Intranasal triamcinolone use during pregnancy and the risk of adverse pregnancy outcomes
    Berard, Anick
    Sheehy, Odile
    Kurzinger, Marie-Laure
    Juhaeri, Juhaeri
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2016, 138 (01) : 97 - +
  • [45] Intranasal Triamcinolone Use during Pregnancy and the Risk of Adverse Pregnancy Outcomes
    Berard, A. B.
    Sheehy, O. S.
    Kurzinger, M. L. K.
    Juhaeri, J. J.
    [J]. BIRTH DEFECTS RESEARCH PART A-CLINICAL AND MOLECULAR TERATOLOGY, 2015, 103 (05) : 410 - 410
  • [46] Intranasal Triamcinolone Use during Pregnancy and the Risk of Adverse Pregnancy Outcomes
    Berard, Anick
    Sheehy, Odile
    Kurzinger, Marie-Laure
    Juhaeri, Juhaeri
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2015, 24 : 255 - 255
  • [47] Is There a Relationship between Adverse Pregnancy Outcomes and Future Development of Atherosclerosis?
    Poznyak, Anastasia V.
    Khotina, Victoria A.
    Zhigmitova, Elena B.
    Sukhorukov, Vasily N.
    Postnov, Anton Y.
    Orekhov, Alexander N.
    [J]. BIOMEDICINES, 2023, 11 (09)
  • [48] Ondansetron Use in Pregnancy and Risk of Adverse Fetal Outcomes
    Pasternak, Bjorn
    Svanstrom, Henrik
    Hviid, Anders
    [J]. PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 14 - 14
  • [49] Glucose alteration in pregnancy and risk of adverse neonatal outcomes
    Pintaudi, B.
    Lucisano, G.
    Di Vieste, G.
    D'Ettorre, A.
    Nicolucci, A.
    [J]. DIABETOLOGIA, 2016, 59 : S446 - S446
  • [50] Maternal Age as a Risk Factor for Adverse Pregnancy Outcomes
    Yao, Nicole
    Gomez, Isabella
    Sefah, Narvella
    Benedetto-Anzai, Maria Teresa
    Cheon, Teresa
    Anzai, Yuzuru
    [J]. REPRODUCTIVE SCIENCES, 2022, 29 (SUPPL 1) : 48 - 48